Giulio Metro

14PUBLICATIONS
164CO-AUTHORS
Predictive and prognostic markersMolecular targetsLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 17, 2026
Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

|Aug 20, 2025
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.

Andrea Botticelli, Chiara Cremolini, Simone Scagnoli

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

Pageof 3

Frequent Collaborators

4 joint publications

Biagio Ricciuti

3 joint publications

Federico Cappuzzo

3 joint publications

Mihaela Aldea

3 joint publications

Laura Bonanno